## Appendix 3

|  |  |
| --- | --- |
| MRN |  |
| surname |  |
| first name |  |
| middle name |  |
| sex |  |
| ever gravid? |  |
| # of pregnancies |  |
| transfusion history |  |
| transfusion reaction history |  |
| DOB |  |
| date of reaction |  |
| age time of reaction (YEARS) |  |
| date of admission |  |
| past medical history |  |
| reason for admission |  |
| facility |  |
| **associated with transfer to ICU or any other escalation of care**? |  |
| date of discharge |  |
| discharge: live or dead |  |
| LOS (DAYS) |  |
| days from reaction to death among fatal cases |  |
| days from admission to reaction |  |
| days from reaction to discharge among survivors |  |
| previously known allergies |  |
| chills/ rigors |  |
| rash (% TBSA) |  |
| dyspnea |  |
| wheeze |  |
| lip / tongue swelling |  |
| pain (& where, if any) |  |
| bleeding / oozing |  |
| hematuria |  |
| nausea or vomiting |  |
| other |  |
| TEMP (observed days up to reaction & immediate pre) |  |
| TEMP (immediate post, & observed days afterward) |  |
| high risk (HR) vs low risk (LR) fever  or not applicable (NA) |  |
| HR |  |
| HR |  |
| BP |  |
| BP |  |
| RR |  |
| RR |  |
| saO2 |  |
| saO2 |  |
| CXR |  |
| CXR |  |
| ABG (BEST OR MOST RECENT) |  |
| ABG (WORST OR CLOSEST) |  |
| cardioresp or volume parameters pre |  |
| cardioresp or volume parameters post |  |
| PRODUCT(s) |  |
| administered via (which vascular access) |  |
| CMV status of patient |  |
| SPECIAL PRODUCT ATTRIBUTES |  |
| AGE OF UNIT |  |
| PRE-MEDICATION |  |
| TIME STARTED |  |
| TIME COMPLETED |  |
| TIME AT REACTION |  |
| POST-MEDICATION |  |
| PROPORTION OF PRODUCT TRANSFUSED |  |
| mode of crossmatching |  |
| PRODUCT ABO type |  |
| other donor antigens of relevance (Ag+ / units tested / units given) |  |
| other donor antibodies of relevance (or donor sex) |  |
| patient pre-transfusion DAT |  |
| patient post-transfusion DAT |  |
| evaluate, if + |  |
| patient pre-transfusion screen |  |
| patient post-transfusion screen |  |
| patient pre-transfusion ABO type |  |
| patient post-transfusion ABO type |  |
| other relevant antigen typing information on patient |  |
| **hemolytic parameter changes pre/post (if any)** |  |
| anti-leukocyte antibodies found in case (HLA: PRA) |  |
| patient cultures before transfusion (most recent negative or active positives) |  |
| pre-transfusion antibiotics |  |
| culture of product |  |
| post-transfusion antibiotics |  |
| patient cultures after transfusion (soonest positive or negative if so) |  |
| co-component or donor lookback findings |  |
| preceding ANC / WBC & shifts (decreases or increases) afterwards |  |
| pre-transfusion abnormality for which blood was indicated (triggering value & symptoms) |  |
| was this a preventable event by following HTC guidelines? |  |
| **error/incident** |  |
| who ordered the blood (& credentials) (eg. resident MD, NP, MRP) |  |
| **probability** |  |
| **diagnosis** |  |
|  |  |
| **probability** |  |
| **diagnosis** |  |
|  |  |
| **probability** |  |
| **diagnosis** |  |
|  |  |
| **probability** |  |
| **diagnosis** |  |
|  |  |
| **probability** |  |
| **diagnosis** |  |
| **imputability/relationship** of product(s) to disturbance |  |
| **grade/severity** of disturbance |  |
| **Outcome** |  |
|  |  |

##